WHO publishes fungal disease blueprint
Analysis based on 6 articles · First reported Jun 30, 2026 · Last updated Jun 30, 2026
The new guidance from the World Health Organization could stimulate research and development in antifungal medicines and diagnostics, potentially benefiting pharmaceutical and biotechnology companies. Increased awareness and investment in public health systems globally may also create opportunities for healthcare providers and related industries.
The World Health Organization has published a new Blueprint for strengthening responses to fungal disease and antifungal resistance. This guidance aims to help countries improve prevention, diagnosis, treatment, and surveillance of fungal diseases, which affect over 300 million people annually and are associated with high mortality. The Blueprint addresses critical gaps in national health plans and antimicrobial resistance strategies, building on the World Health Organization's Fungal Priority Pathogens List. It prioritizes interventions across four domains: public health and health systems, advancement of therapies and innovation, laboratory systems and surveillance, and social and environmental drivers. Jean-Pierre Nyemazi and Hatim Sati from the World Health Organization emphasized the importance of this initiative.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard